Traws Pharma, Inc. (TRAW)

Traws Pharma Statistics

Total Valuation

Traws Pharma has a market cap or net worth of $14.69 million. The enterprise value is $410,913.

Market Cap	14.69M
Enterprise Value	410,913

Important Dates

The next estimated earnings date is Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Traws Pharma has 7.06 million shares outstanding. The number of shares has increased by 439.67% in one year.

Current Share Class	7.06M
Shares Outstanding	7.06M
Shares Change (YoY)	+439.67%
Shares Change (QoQ)	-19.32%
Owned by Insiders (%)	5.19%
Owned by Institutions (%)	9.31%
Float	6.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.14
Forward PS	110.23
PB Ratio	1.63
P/TBV Ratio	1.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.09

Current Ratio	2.09
Quick Ratio	1.96
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -248.20% and return on invested capital (ROIC) is -176.40%.

Return on Equity (ROE)	-248.20%
Return on Assets (ROA)	-73.84%
Return on Invested Capital (ROIC)	-176.40%
Return on Capital Employed (ROCE)	-245.05%
Revenue Per Employee	$414,714
Profits Per Employee	-$728,286
Employee Count	7
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.87% in the last 52 weeks. The beta is 1.52, so Traws Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.52
52-Week Price Change	-75.87%
50-Day Moving Average	1.57
200-Day Moving Average	3.27
Relative Strength Index (RSI)	78.32
Average Volume (20 Days)	104,411

Short Selling Information

The latest short interest is 102,595, so 1.45% of the outstanding shares have been sold short.

Short Interest	102,595
Short Previous Month	162,903
Short % of Shares Out	1.45%
Short % of Float	1.70%
Short Ratio (days to cover)	0.77

Income Statement

In the last 12 months, Traws Pharma had revenue of $2.90 million and -$5.10 million in losses. Loss per share was -$1.07.

Revenue	2.90M
Gross Profit	2.90M
Operating Income	-20.27M
Pretax Income	-18.16M
Net Income	-5.10M
EBITDA	-20.26M
EBIT	-20.27M
Loss Per Share	-$1.07

Balance Sheet

The company has $13.08 million in cash and n/a in debt, giving a net cash position of $13.08 million or $1.85 per share.

Cash & Cash Equivalents	13.08M
Total Debt	n/a
Net Cash	13.08M
Net Cash Per Share	$1.85
Equity (Book Value)	8.26M
Book Value Per Share	1.17
Working Capital	8.02M

Cash Flow

Operating Cash Flow	-26.93M
Capital Expenditures	n/a
Free Cash Flow	-26.93M
FCF Per Share	-$3.81

Margins

Gross Margin	100.00%
Operating Margin	-698.11%
Pretax Margin	-613.92%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Traws Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-439.67%
Shareholder Yield	-439.67%
Earnings Yield	-37.79%
FCF Yield	-199.62%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.

Last Split Date	Sep 23, 2024
Split Type	Reverse
Split Ratio	1:25

Scores

Traws Pharma has an Altman Z-Score of -58.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-58.71
Piotroski F-Score	2